GL 48656

Drug Profile

GL 48656

Alternative Names: GL-48656

Latest Information Update: 04 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genelabs Technologies
  • Class Antifungals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Aspergillosis

Most Recent Events

  • 26 Sep 2003 Data presented at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial infections antimicrobial activity and pharmacodynamics section ,,
  • 16 Sep 2003 GL 48656 is available for licensing (http://genelabs.com)
  • 26 Mar 2003 Preclinical trials in Aspergillosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top